Todos Medical Overview
Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The company's Todos Biochemical Infrared Analyses comprise proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test is a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies.
Cumulative Funding Raised Over Time ($)
$1.4MFeb 2019
$4.8MJan 2021
Latest News
growth-negative
Todos Medical Announces Insolvency Proceedings in Israel
Todos Medical Ltd. is facing insolvency issues following a lawsuit filed by its former CEO, Rami Zigdon, for unpaid wages. A trustee has been appointed to oversee the liquidation of the company in Israel. The company has submitted a reorganization plan to the trustee to avoid liquidation. Todos Medicals subsidiary, 3CL Pharma USA, Inc., has also received a notice of default from its licensor, NLC Pharma, Ltd., for unpaid fees. The company is seeking to raise $1,000,000 by December 29, 2023 to meet its obligations.
InvestmentManagement ChangesCustomers
growth-positive
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Todos Medical Ltd. has announced its plans to focus on addressing the Long COVID epidemic affecting over 15 million Americans. The company intends to deploy medical foods, nutritional supplements, and diagnostic panels to assist in the diagnosis and monitoring of Long COVID patients. Todos has also finalized a new agreement with NLC Pharma, Ltd. to license dietary supplement Tollovid, therapeutic candidate Tollovir, and biomarker assay TolloTest. The company is now able to swiftly implement its strategy of crowdfunding within the 3CL Pharma entity to fund a Long COVID clinical trial.
PartnersInvestmentExpand
growth-positive
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Todos Medical Ltd. provided a corporate update focusing on its efforts to address the Long COVID epidemic. The company has finalized a new agreement with NLC Pharma to license dietary supplement Tollovid, therapeutic candidate Tollovir, and biomarker assay TolloTest. Todos plans to deploy these products to aid in the dietary management, immune support, and diagnosis of Long COVID. The agreement grants Todos exclusive rights in the U.S., Canada, Mexico, Ghana, and the Caribbean. The company aims to fund a Long COVID clinical trial through crowdfunding and expects to announce further details soon. Additionally, Todos intends to leverage its equity ownership in 3CL Pharma to create shareholder value.
Partners
growth-positive
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Todos Medical has announced that the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance for NLC Pharmas patent application for compounds used in the treatment of coronavirus infection. The allowed claims cover the administration of compounds to inhibit the activity of the 3CL protease, inflammation, and autophagy. The patentability of the compounds has been validated, but their approvability as a disease treatment is subject to the United States Food & Drug Administration (US FDA). Todos Medical is a medical diagnostics and solutions company that focuses on the early detection of various cancers. The company has also developed a dietary supplement called Tollovid, which is a 3CL protease inhibition dietary supplement.
Investment
growth-positive
Todos Medical's Letter of Intent with Provista Diagnostics set to license sepsis diagnostic testing
Todos Medical has entered into a Letter of Intent with Provista Diagnostics to license PCR-based sepsis diagnostic test AcuSept LDT rights from Acumen Diagnostics. Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers using their proprietary Todos Biochemical Infrared Analyses (TBIA) technology. The partnership with Provista Diagnostics will contribute to the companys growth in the field of diagnostics.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.45M |
| Last funding | $3.4M |
| Stage | Public |
| Rounds | 4 |
| Investors | 2 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | todosmedical.com |
| Careers | Careers page |
Locations
Derech Menachem Begin 121, Tel Aviv-Yafo, Israel
40 Wall Street, New York, NY, USA
Photos & Videos
2 item(s)
Todos Medical Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcareProvidersLaboratoriesCore Technology
BiologicalsSensingInfraredTags (10)
alzheimers-diseasespectroscopydetectioninfraredmedical-technologiesblood-testcancerdiagnosticsscreeningearly-detectionGeographic Markets
IsraelIndiaUnited StatesRomaniaAustriaEuropeTodos Medical Financials
$3.45M
Total funding
Undisclosed
Capital raised
$3.4M
Last funding
Public
Funding stage
4
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$1.4MFeb 2019
$4.8MJan 2021
Private Equity Funding
Convertible Debt
Jan 2021
$3.4M
The Yozma Group
Debt Financing
Feb 2019
$1.35M
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
May 2016
$54.2K
EASME - EU Executive Agency for SMEs
Public Offering / Exit
POEvent
Feb 2016
Undisclosed
Mergers & Acquisitions
MNAEvent
Apr 2021
$7.5M
Todos Medical Lifecycle
Cumulative Funding Raised Over Time
$1.4MFeb 2019
$4.8MJan 2021
All Events
Convertible Debt
Jan 2021
$3.4M
The Yozma Group
Debt Financing
Feb 2019
$1.35M
Undisclosed Investor(s)
GrantEvent
May 2016
$54.2K
EASME - EU Executive Agency for SMEs
POEvent
Feb 2016
Undisclosed
MNAEvent
Apr 2021
$7.5M
Todos Medical News
52 articles
growth-negative
Todos Medical Announces Insolvency Proceedings in Israel
Todos Medical Ltd. is facing insolvency issues following a lawsuit filed by its former CEO, Rami Zigdon, for unpaid wages. A trustee has been appointed to oversee the liquidation of the company in Israel. The company has submitted a reorganization plan to the trustee to avoid liquidation. Todos Medicals subsidiary, 3CL Pharma USA, Inc., has also received a notice of default from its licensor, NLC Pharma, Ltd., for unpaid fees. The company is seeking to raise $1,000,000 by December 29, 2023 to meet its obligations.
InvestmentManagement ChangesCustomers
growth-positive
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Todos Medical Ltd. has announced its plans to focus on addressing the Long COVID epidemic affecting over 15 million Americans. The company intends to deploy medical foods, nutritional supplements, and diagnostic panels to assist in the diagnosis and monitoring of Long COVID patients. Todos has also finalized a new agreement with NLC Pharma, Ltd. to license dietary supplement Tollovid, therapeutic candidate Tollovir, and biomarker assay TolloTest. The company is now able to swiftly implement its strategy of crowdfunding within the 3CL Pharma entity to fund a Long COVID clinical trial.
PartnersInvestmentExpand
growth-positive
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Todos Medical Ltd. provided a corporate update focusing on its efforts to address the Long COVID epidemic. The company has finalized a new agreement with NLC Pharma to license dietary supplement Tollovid, therapeutic candidate Tollovir, and biomarker assay TolloTest. Todos plans to deploy these products to aid in the dietary management, immune support, and diagnosis of Long COVID. The agreement grants Todos exclusive rights in the U.S., Canada, Mexico, Ghana, and the Caribbean. The company aims to fund a Long COVID clinical trial through crowdfunding and expects to announce further details soon. Additionally, Todos intends to leverage its equity ownership in 3CL Pharma to create shareholder value.
Partners
growth-positive
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Todos Medical has announced that the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance for NLC Pharmas patent application for compounds used in the treatment of coronavirus infection. The allowed claims cover the administration of compounds to inhibit the activity of the 3CL protease, inflammation, and autophagy. The patentability of the compounds has been validated, but their approvability as a disease treatment is subject to the United States Food & Drug Administration (US FDA). Todos Medical is a medical diagnostics and solutions company that focuses on the early detection of various cancers. The company has also developed a dietary supplement called Tollovid, which is a 3CL protease inhibition dietary supplement.
Investment
growth-positive
Todos Medical's Letter of Intent with Provista Diagnostics set to license sepsis diagnostic testing
Todos Medical has entered into a Letter of Intent with Provista Diagnostics to license PCR-based sepsis diagnostic test AcuSept LDT rights from Acumen Diagnostics. Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers using their proprietary Todos Biochemical Infrared Analyses (TBIA) technology. The partnership with Provista Diagnostics will contribute to the companys growth in the field of diagnostics.
Partners
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Todos Medical Begins Trading on the OTC Pink Marketplace
Todos Medical Supports Long COVID Awareness Day
growth-positive
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Todos Medical Ltd. has entered into a new agreement with holders of its convertible notes, providing a 21-day moratorium on conversion. The company aims to balance immediate capital requirements with a plan that maintains its OTCQB listing requirement over $.001. The agreement is designed to provide time for Todos to negotiate a new financing agreement with its existing noteholders. The companys share price has recently declined sharply, creating uncertainty in the biotech securities marketplace. Todos is hopeful to work out a longer-term agreement that will create a roadmap for the company to continue its pursuit of its crowdfunding capital raise for its majority-controlled subsidiary 3CL Pharma.
InvestmentPartners
growth-positive
Todos Medical releases corporate update around validation plan for PCR-based Avian Influenza testing
Todos Medical CEO discusses the validation plan for PCR-based Avian Influenza A (H5N1, bird flu) human testing and the companys growth across projects and subsidiary 3CL Pharma.
Investment
Todos Medical Provides Corporate Update
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
growth-positive
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Todos Medical Ltd. announced that its majority-owned subsidiary 3CL Pharma was awarded oral and poster presentations at the World Antiviral Congress 2022. The presentations will showcase the companys 3CL inhibitors and their application in treating COVID-19. The company also highlighted its product Tollovid, an immune support dietary supplement, and Tollovir, a therapeutic drug candidate. Todos Medical is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimers disease.
CustomersExpand
Todos Medical to Attend World Antiviral Congress
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Todos Medical Announces Third Quarter 2022 Financial Results
Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Todos Medical Announces BioFuture™ NYC 2022 Presentation
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Presenting on the Emerging Growth Conference on October 12 Register Now
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
growth-positive
Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test
Todos Medical Ltd. has acquired Provista Diagnostics, a medical diagnostics company based in Alpharetta, Georgia. Provista owns the intellectual property rights to the proprietary breast cancer blood test, Videssa®, and has a diagnostic testing laboratory performing COVID-19 PCR testing. The acquisition will allow Todos to commercialize Videssa and expand Provistas capabilities in COVID variant identification. The breast cancer diagnostics market reached a size of over $19 billion in 2019. Todos plans to launch Videssa by the end of 2021 and work with key opinion leaders to expand its clinical validation. Todos also aims to deploy its proprietary TBIA immunosurveillance blood testing assay for breast cancer and other cancers. The acquisition price for Provista was $7.5 million, consisting of cash, common shares, and a convertible promissory note.
PartnersCustomers
growth-positive
Todos Medical Announces Strategic Investment by Yozma Group Korea
Todos Medical has announced a $3.4 million strategic investment from Yozma Group Korea. The investment will be used to retire outstanding convertible notes, complete the acquisition of Provista Diagnostics, and for general working capital. Todos Medical is an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, as well as developing blood tests for early detection of cancer and Alzheimers disease. Yozma Group Korea sees a significant opportunity to fuel Todos growth and drive cross-border collaboration in South Korea. The investment is seen as a significant milestone for Todos and will allow the company to aggressively pursue sales growth expansion.
Investment
growth-positive
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Todos Medical has entered into a preferred vendor agreement with Natural Wellness Clinics (NWC) to supply COVID-19 testing products and services for the uninsured population in Kentucky. NWC recently signed a testing contract with the Commonwealth of Kentucky worth approximately $93.4 million, but budget concerns have impacted the initiative. Todos is working with the Commonwealth of Kentucky to identify alternative funding mechanisms. The partnership with NWC will serve as a model for delivering comprehensive testing solutions. Todos Medical is an in vitro diagnostics company focused on COVID-19 screening and diagnosis, as well as developing blood tests for early detection of cancer and Alzheimers disease.
CustomersPartners
growth-positive
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Todos Medical Ltd. has announced total revenues of $2.0 million for the third quarter of 2020. The revenues were primarily derived from sales of ANDis 350 automated extraction machines and related extraction reagent kits, as well as deposits for ongoing reagent supply agreements. The company has received its first payments from its largest client in Wisconsin, who is rapidly scaling its capacity with Todos solutions in the face of increased demand for PCR testing. Todos expects to generate revenue from FDA EUA approved qPCR kits sold in their PCR packages in November 2020. The company has entered into contracts that have the potential to generate revenues of $60 million by the end of the first half of 2021. They aim to become cash flow positive in the middle of the fourth quarter of 2020.
CustomersInvestment
growth-positive
https://www.jpost.com/israel-news/israeli-diagnostic-company-partners-with-aid-genomics-on-covid-19-testing-643701
Todos Medical Ltd. has entered into an implementation and equipment financing partnership with AID Genomics for COVID-19 testing. AID Genomics will finance the purchase of equipment needed to meet capacity requirements for Todos clients. They will also assist in scaling and optimizing sample accessioning and data reporting software. AID Genomics will receive part of the net profit of each contract and will help Todos validate and commercialize proprietary tests in Israel. Todos Medical plans to pursue new laboratory equipment and reagent supply agreements with the non-dilutive funding provided by the partnership. Todos Medical is an Israeli company that develops testing for the early detection of various cancers.
Partners
growth-positive
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Todos Medical Ltd. has announced that NLC Pharma has added the dietary supplement NLC-001 to its joint venture with Todos Medical. NLC-001 is an orally administered proprietary blend of plant extracts that includes a powerful potential 3CL protease inhibitor that could help support and maintain healthy immune function. Todos has been granted exclusive worldwide distribution rights for various formulations of NLC-001, excluding Israel, as well as a right of first refusal to develop pharmaceutical drugs based on the NLC technology. Todos is responsible for all commercial activities, including manufacturing, clinical testing, marketing and distribution outside of Israel.
PartnersExpand
growth-positive
Nationwide On-Site Coronavirus Testing Program
Meridian HSN has partnered with Moto-Para and Todos Medical to provide a complete turnkey solution for on-site COVID testing. The partnership allows Meridian HSN to set up testing sites anywhere in the US. Todos Medical supplies the test kits and robotic equipment, while Moto-Para provides the medical staff. The cost of testing is determined by volume and sources of funding. Meridian HSN also supplies Personal Protective Equipment (PPE) for testing and long-term needs. The article emphasizes the importance of data collection, telemedicine, and rapid results delivery. Meridian HSN is a healthcare services network that helps manage and lower health, benefits, and risk management costs. Todos Medical is an Israeli company that engineers diagnostic solutions for early cancer detection.
PartnersCustomers
growth-positive
Todos Medical Enters Into Distribution Partnership With Meridian Health Services Network for COVID-19 Testing Solutions
Todos Medical Ltd. has announced a partnership with Meridian Health Services Network to deploy COVID-19 testing programs throughout the United States. As part of the agreement, Todos will be working closely with Meridian to help supplement COVID-19 testing products and services for its network of brick & mortar and mobile laboratories nationwide. Meridian successfully completed CLIA validation testing for Todos’ antibody test. The partnership will allow Todos to supply a full set of PCR and antibody testing solutions for COVID-19 to a nationwide health network.
PartnersExpand
growth-positive
Todos Medical Enters Into Exclusive Distribution Agreement With NLC Pharma for Saliva-based Onsite COVID-19 Diagnostic Test
Todos Medical Ltd. has entered into an exclusive worldwide distribution agreement with NLC Pharma to develop its patented virus-focused 3C Protease diagnostic platform for the diagnosis of COVID-19. Todos intends to develop an At-Home COVID-19 diagnostic test kit using the 3C Protease technology. The companies will work towards filing an Emergency Use Authorization application with the FDA. The technology will allow for integration with various contact tracing, telehealth, and employer-based health solutions. NLC Pharma previously developed prototypes for rapid detection of other viruses. Todos Medical is an in vitro diagnostics company focused on COVID-19 screening and diagnosis, as well as the development of blood tests for cancer and Alzheimers disease.
PartnersInvestment
growth-positive
Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar
Todos Medical Ltd. has expanded its exclusive distribution agreement with Gibraltar Brothers & Associates, LLC to include PCR testing kits in addition to colloidal gold IgM/IgG immunochromatography antibody test. The company will be commercializing the PCR kits through its COVID-19 focused joint venture with Emerald Organic Products, Inc. The agreement grants Todos exclusive rights to distribute the kits in various Asian countries, including Singapore, Malaysia, Indonesia, and Japan. Dr. Joseph Wee, CEO of Todos Medical Singapore, will lead the commercialization effort in Asia. The expansion is expected to have a positive impact on the companys growth.
CustomersPartners
growth-positive
https://www.jpost.com/jpost-tech/hillels-tech-corner-todos-medical-revisited-amid-the-corona-pandemic-622591
Todos Medical Ltd., an in-vitro diagnostic company, has made the decision to pivot and allocate significant resources to COVID-19 testing. The company has purchased testing kits and signed agreements with two companies for distribution. They are also in negotiations with additional manufacturers. Todos has a CLIA lab in Atlanta and will validate the tests before selling them to the public. They have also announced a partnership with Emerald Organic for regulatory approval. The company aims to provide testing to as many people as possible, as tests are in high demand and low supply. This decision to focus on COVID-19 testing has a growth-positive impact on the company.
CustomersPartners
growth-positive
Todos Medical Signs Novel Coronavirus (COVID-19) Point-of-Care Rapid Antibody Testing Kit Exclusive Distribution Agreement for the United States and Israel with Shanghai Liangrun Subsidiary Gibraltar
Todos Medical Ltd., a pre-commercial stage in-vitro diagnostics company, has entered into an exclusive distribution agreement for the United States and Israel with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. The agreement is for the distribution of its proprietary colloidal gold immunochromatography test, which has been approved as a diagnostic test for COVID-19 in China and Europe. Todos will be responsible for obtaining U.S. FDA approval and plans to do so under the Emergency Use Authorization Program.
PartnersExpand
growth-positive
Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel
Todos Medical Ltd. has entered into a distribution agreement with 3DMedicine Science & Technology Co (3DMed) for the distribution of 3DMeds COVID-19 testing kits and automated PCR machine in the US and Israel. The agreement aims to provide additional testing capacity for the ongoing coronavirus pandemic. 3DMeds testing kits have received CE Mark and China FDA approval, and the company is currently in discussions with the US FDA for approval. The key theme of the article is the partnership between Todos Medical and 3DMed for the distribution of COVID-19 testing products. The article discusses the combination of coronavirus and influenza A/B testing in one kit, which is seen as a novel approach in the United States. The article does not mention any specific customers, acquisition or investment amounts, layoffs, or management changes. The date of the event described in the article is March 17, 2020. My confidence in this answer is 8/10.
Partners
growth-positive
Todos Medical Receives Notice of Allowance from European Patent Office Covering Diagnosis of Solid Tumors Using AI to Analyze Blood
Todos Medical Ltd. has received a notice of allowance from the European Patent Office for the use of its proprietary Total Biochemical Infrared Analysis (TBIA) platform to identify solid tumors using peripheral blood mononuclear cells (PBMCs). The patent covers the use of Fourier Transformed Infrared Analysis (FTIR) spectroscopy and artificial intelligence to build algorithms predictive of different types of solid tumors. The company expects the patent to be issued soon. This expansion of Todos intellectual property portfolio is significant as it could potentially be used as a broad screening tool for all cancers, representing a sea-change in cancer screenings for health systems. Todos Medical is a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders.
Partners
growth-positive
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
Todos Medical Ltd. has announced its plans to relocate its headquarters from Israel to the United States. The company has also entered into an exclusive option agreement to acquire Provista Diagnostics, an in vitro diagnostics company specializing in the development of the Videssa blood test for breast cancer. The Videssa blood test has been clinically validated for the early and accurate detection of breast cancer. Todos Medical aims to become a premier breast cancer blood testing company with the potential to expand its leadership position to all cancers. The company has appointed a new CEO and CFO to lead the relocation efforts and focus on the development and commercialization of its cancer diagnostic platform in the US.
AcquisitionManagement Changes
growth-positive
Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries
Todos Medical Ltd. has signed a Distribution Agreement with Orot+ for exclusive distribution rights of its blood tests for breast cancer screening in Romania and Austria. Orot+ will be responsible for marketing and distribution costs and execution associated with commercializing the breast cancer tests in these territories. Todos Medical will be able to use the data gathered from these initiatives to support further development and commercialization in other jurisdictions. The agreement marks an important milestone for Todos Medical in establishing a local network to introduce their cancer screening tests to the European market.
Partners
growth-positive
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer's Blood Diagnostic LymPro Test 2.0
Todos Medical Ltd. and Amarantus Bioscience Holdings have announced the completion of the LymPro PET 1 study, a clinical trial for the immune-based Alzheimers blood diagnostic LymPro Test 2.0. Todos will evaluate the data from the clinical trials to inform their regulatory strategy for LymPro commercialization. They plan to initially deploy the assay to support pharmaceutical trials while generating additional data for market authorization. Todos has the option to acquire full control of Breakthrough Diagnostics, the joint venture between Todos and Amarantus, in exchange for issuing more shares to Amarantus.
PartnersInvestment
growth-positive
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
Todos Medical Ltd. has announced the appointment of Dr. Colin Bier to its Board of Directors. Dr. Bier brings expertise in the commercialization of diagnostic tests and will be an asset to the company as it navigates the regulatory landscape and seeks to bring its diagnostic tests to the broader physician-patient community. Todos Medical is a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders. The company has developed two cancer screening tests and owns the exclusive rights to the Lymphocyte Proliferation Test (LymPro Test), a diagnostic blood test for Alzheimers disease.
Management Changes
growth-positive
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
Todos Medical Ltd. has raised $1,350,500 from private investors and closed a Joint Venture transaction with Amarantus Bioscience. Todos Medical issued 19.99% of its outstanding ordinary shares to Amarantus in exchange for 19.99% of Amarantuss subsidiary Breakthrough Diagnostics. Todos Medical will focus on the development of the LymPro Test 2.0, a diagnostic blood test for Alzheimers disease. The company aims to improve early diagnosis of the disease, which affects 5.2 million Americans. Todos Medical has an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics. The investment and acquisition are expected to drive the clinical and commercial plan for LymPro and deliver significant shareholder value.
InvestmentAcquisition
growth-positive
Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)
Todos Medical Ltd. will be attending the 2018 San Antonio Breast Cancer Symposium to present the clinical trial results of its TM-B1 cancer test. The company believes that the findings will demonstrate the effectiveness of its blood-based technology platform for early cancer detection. Todos Medical is a clinical-stage in-vitro diagnostics company focused on the development of blood tests for cancer detection. They have developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), which are CE marked in the EU.
Customers
growth-positive
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
Todos Medical has been granted an additional patent for its inventions relating to the indication of a presence of cancerous breast tissue based on a blood test. The patent strengthens the companys breast cancer screening tests and is expected to improve the accuracy of diagnosis. Todos Medical believes that their approach to detecting tumors through blood samples combined with spectroscopy can improve patient morbidity and mortality rates. The patent is set to expire on May 10, 2033.
Customers
growth-positive
Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria
Todos Medical Ltd. has signed a non-binding memorandum of understanding with Orot+ for proposed sole distribution rights of its blood tests for breast cancer screening in Romania and Austria. The purpose of the agreement is for Orot+ to establish regulatory approvals, markets, and applications for the distribution of Todos screening tests. Orot+ will conduct a pilot in Romania and Austria, and in return, is expected to receive shares of Todos common stock. Todos Medical is focused on the development of blood tests for the early detection of cancer. The partnership with Orot+ is expected to help introduce their breast cancer screening tests to the European market.
Partners
growth-positive
Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer
Todos Medical Ltd. has appointed Herman Weiss, MD MBA as the new Chief Executive Officer of the company. Dr. Weiss succeeds Rami Zigdon, MBA, who will now hold the position of Chief Business Officer. The company intends to re-appoint Dr. Weiss as Chairman of the Board of Directors, subject to approval by the company’s shareholders. Todos Medical Ltd. is an Israeli cancer in-vitro-diagnostic company that develops blood tests for the early detection of various cancers. The company has developed two cancer screening tests based on Todos Biochemical Infrared Analyses (TBIA), a method that uses peripheral blood analysis. The tests are CE marked in the EU.
Management Changes
growth-positive
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
Todos Medical Ltd. announced the results of a clinical trial for their proprietary TM - B1 Assay for breast cancer screening. The trial showed a high degree of accuracy in identifying healthy versus benign versus breast cancer in female subjects. The company believes that detecting breast cancer at an early stage will be possible through a simple blood test. The TM-B1 test is based on biochemical analysis of blood components and is intended for women aged 25 years and older. Todos Medical is a cancer in-vitro-diagnostic company that develops blood tests for the early detection of various cancers.
Customers
growth-positive
Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening
Todos Medical Ltd. has announced the initiation of its first blinded clinical trial for TM-B1, a simple blood test for breast cancer screening. The study will be conducted in Kaplan Hospital in Israel and will include about 200 patients. The TM-B1 test is based on Total Biochemical Infrared Analysis (TBIA) technology for biochemical analysis of blood components. Previous clinical studies have shown that TBIA was able to detect breast cancer with a sensitivity and specificity of 93% and 87% respectively. Todos Medical is an Israeli company engaged in the development of blood tests for the early detection of various cancers.
Customers
growth-positive
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
Todos Medical has been granted two patents for its inventions related to cancer screening. The patents cover the analysis of infrared spectra of blood samples to indicate the presence of solid tumors in breast tissue and to differentiate between benign and malignant tumors. These patents are seen as important milestones in protecting the companys technology and strengthening its position as a leader in the field. Todos Medical is a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The company has developed two cancer screening tests based on its proprietary TBIA method.
Customers
growth-positive
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
Todos Medical, Ltd. Inc. has announced the hiring of a new CFO, Mr. David Ben Naim. Mr. Ben Naim has a distinguished record as Chief Financial Officer for companies listed in both the United States and Israel. He will be a true asset to the team.
Management Changes
growth-positive
Todos Medical files for Wall St IPO
Todos Medical, an Israeli cancer screening and follow-up company, has filed a prospectus to raise money on Wall Street. The company plans to raise $5 million, with $3 million already raised from private investors. Todos Medical has developed a platform for cancer screening using a blood test. The funds raised will be used to finance clinical trials in Israel, India, and the US. The company aims to introduce new products and expand its market. The potential market for cancer screening is estimated to be 500 million checks annually. Todos Medicals platform aims to provide earlier and cheaper screening options, complementing existing procedures like mammograms and colonoscopies.
Investment
Employee Info
| Employees (range) | 1-10 |
| Exact count | 7 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
Todos Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514437128 |
| Crunchbase | todos-medical |
| Phone | +97286333964 |
| Creator | Arielle Smolin |
| Creator email | ari.smolin@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-08-22T00:00:00.000Z |
| Created | 2014-07-07T00:00:00.000Z |
| Status detail | Public on OTCBB on Feb, 2016<br> |